Skip to content
AlternativeMed

Vitamin K2 (MK-4 and MK-7): Bone and Heart Evidence, Sources and Natto

What vitamin K2 (MK-4 and MK-7) is, where it comes from including natto, and what trials found for bones and arteries, with warfarin and other safety cautions.

Content last updated . This page has not been medically reviewed.

If you take warfarin, read this first

Vitamin K changes how warfarin works. The NHS (UK) says not to take vitamin K supplements while on warfarin, and that foods high in vitamin K can affect it; you can still eat them, but talk to your warfarin clinic. [1] In a study of healthy volunteers on an anticoagulant (acenocoumarol), 45 mcg a day of MK-7 lowered the clotting test (INR) by about 40%, and the authors concluded MK-7 supplements need to be avoided in people on this type of drug. [2] Do not stop or change a prescribed medicine on your own; ask your anticoagulation clinic or pharmacist. See vitamins and blood thinners and medication interactions.

The short answer

Vitamin K2 is a family of compounds called menaquinones. Trials of K2 on bones and arteries are mixed. Most show effects on blood markers; results on fractures and heart outcomes are unclear. For the K1 and K2 contrast, see vitamin K1 vs K2 and the main profile, Vitamin K.

Evidence labels used: established nutritional role, mixed, promising but limited, insufficient evidence, no good evidence of benefit, and "Proper evidence not found". Biomarker change (a blood marker moving) is kept separate from outcomes like fractures.

What K2 is: MK-4 and MK-7

MedlinePlus lists phylloquinone (K1) and menaquinone (K2) as forms of vitamin K, and notes bacteria in the lower intestine also make vitamin K. [3] In a Japanese analysis of 58 foods, K1 was in green vegetables, MK-4 was widely found in animal products, and MK-7 was characteristic of fermented soybean foods such as natto. [4] MK-7 is the long-chain form with a very long half-life, which gives more stable blood levels. [5] Results for one form do not transfer to another.

Food sources and natto

In that analysis natto contained 939 mcg of MK-7 per 100 g. [4] The analysis was Japanese and of the foods tested; amounts differ by product. Because natto is such a concentrated source, people on warfarin should ask their anticoagulation clinic before eating it. Proper evidence not found in the sources we read for a study of natto itself with warfarin. For K1 foods see foods high in vitamin K.

Official intake figures

PopulationFigureBody and year
US males 19+ (Adequate Intake)120 mcg a day [3]MedlinePlus (US), review 2025
US females 19+, including pregnancy and lactation90 mcg a day [3]MedlinePlus (US), review 2025
US ages 14 to 18, including pregnancy and lactation75 mcg a day [3]MedlinePlus (US), review 2025
EU adults including pregnancy and breastfeeding70 mcg phylloquinone (K1) a day [6]EFSA, 2017
UK adultsAbout 1 mcg per kg body weight a day [7]NHS, page reviewed 2020
US label Daily Value120 mcg [8]FDA (label reference, not a requirement)

EFSA set its figure for phylloquinone only, because evidence on menaquinones was insufficient. [6] So no official body we read sets an intake figure for K2 itself. EFSA lists no adequate data to derive an upper level for vitamin K. [9] The NHS says there is not enough evidence to know what high-dose supplements do, and that 1 mg or less a day is unlikely to cause harm. [7] Lack of an upper level does not prove high doses are safe.

Bones

QuestionWhat the source foundStrength
MK-7 and bone loss, 3 years244 healthy postmenopausal women, 180 mcg MK-7 a day: less decline in bone density at the lumbar spine and femoral neck, but not the total hip [10]Promising but limited
MK-7 as natto capsules, 1 year334 Norwegian women, 360 mcg a day: no difference in bone loss [11]No good evidence of benefit
K2 in Chinese adults, 1 year90 mcg a day reduced femoral neck bone loss in postmenopausal women, but not in men [12]Mixed
Systematic review of 36 trials of oral vitamin K, any form (Mott 2019)No evidence vitamin K affects bone density or vertebral fractures; it may reduce clinical fractures; evidence insufficient [13]Insufficient evidence
Menatetrenone (MK-4 medicine) meta-analysisLower undercarboxylated osteocalcin and maybe better lumbar density; fracture benefit uncertain; more adverse events but not more serious ones [14]Mixed

An earlier review found large fracture reductions, but all seven trials with fracture data were Japanese and used menaquinone-4. [15] The 2019 update noted that the integrity of some of the earlier evidence had been questioned. [13] The NHS says there is some evidence vitamin K may help keep bones healthy. [7] Osteoporosis treatment is clinician-led; see osteoporosis and bone health and vitamin D, falls and fractures.

Heart and arteries

QuestionWhat the source foundStrength
Eating more menaquinone (Rotterdam Study, 4,807 people)Higher menaquinone intake was linked to lower coronary heart disease death and severe aortic calcification; phylloquinone was not [16]Observational only
Aortic valve calcification (AVADEC)365 men, 720 mcg MK-7 plus 25 mcg vitamin D for 24 months: no effect on progression [17]No good evidence of benefit
Coronary calcification, same trial groupNo significant reduction overall; fewer in the highest-score subgroup, described as hypothesis-generating [18]Insufficient evidence
Coronary calcification (VitaK-CAC, 2026)180 people with symptomatic coronary disease, 360 mcg MK-7 a day for 2 years: slower calcium score rise; clinical meaning not known [19]Promising but limited
Systematic review of arterial trialsVitamin K does not consistently prevent progression of calcification or artery stiffness [20]Mixed

Calcium scores and artery stiffness are markers; none of these trials showed that K2 prevents heart attacks. [20] See vitamin supplements and heart disease and D3 with K2 versus D3 alone.

Kidney disease and dialysis

A meta-analysis of 11 dialysis trials (830 people) found vitamin K had no effect on mortality and no significant benefit in reversing calcification scores. [21] A 96-patient trial found 375 mcg a day of MK-7 did not change arterial stiffness overall, though it did in a diabetes subgroup. [22] People with kidney disease should only use vitamin K supplements under their kidney team; we did not find a source on liver disease and K2, so ask your care team.

Frequently asked questions

Is vitamin K2 better than K1?

We could not read a head-to-head trial with health outcomes. In dialysis patients, K1 lowered a calcification marker more than K2, but that is a marker. [21]

Does vitamin K2 build bone or prevent fractures?

Mixed. Some MK-7 and K2 trials slowed bone loss; one 1-year MK-7 trial did not, and the 2019 review found insufficient evidence on fractures. [10][11][13]

Does vitamin K2 clear arteries?

Not shown. AVADEC found no effect on aortic valve calcification, and reviews found inconsistent effects on calcification. [17][20]

Is natto a good source of K2?

In one Japanese analysis natto had 939 mcg MK-7 per 100 g, but anyone on warfarin must ask their clinic first. [4][1]

Can I take K2 with warfarin?

The NHS says not to take vitamin K supplements on warfarin, and a study found MK-7 at 10 mcg a day affected the INR in some people. Ask your anticoagulation clinic. [1][2]

More details: evidence, limits and cautions

The details behind this page: cautions, limits of the evidence and where sources disagree. Open any note to read it.

Safety and who should ask first
Ask a clinician or pharmacist before using K2 if you take warfarin or other anticoagulants, have a clotting disorder, are pregnant or breastfeeding, have kidney disease, or have surgery planned. We found no study of K2 supplements in pregnancy or in children; for newborns see vitamin K deficiency bleeding. See supplements before surgery and quality testing. A blood marker of vitamin K status (such as osteocalcin) is not a diagnosis; do not treat a suspected deficiency alone.
References
  1. NHS (UK). Warfarin. Read 2026-10-23.
  2. Theuwissen E et al. 2013. Effect of low-dose supplements of menaquinone-7 (vitamin K2 ) on the stability of oral anticoagulant treatment: dose-response relationship in healthy volunteers. Journal of thrombosis and haemostasis : JTH. PMID 23530987. Read 2026-10-23.
  3. MedlinePlus (US National Library of Medicine). Vitamin K. Review date 1/21/2025. Read 2026-10-23.
  4. Kamao M et al. 2007. Vitamin K content of foods and dietary vitamin K intake in Japanese young women. Journal of nutritional science and vitaminology. PMID 18202532. Read 2026-10-23.
  5. Schurgers LJ et al. 2007. Vitamin K-containing dietary supplements: comparison of synthetic vitamin K1 and natto-derived menaquinone-7. Blood. PMID 17158229. Read 2026-10-23.
  6. Turck D et al. 2017. Dietary reference values for vitamin K. EFSA journal. European Food Safety Authority. PMID 32625486. Opinion abstract read on PubMed (publisher page returned HTTP 403). Read 2026-10-23.
  7. NHS (UK). Vitamin K. Page last reviewed 3 August 2020. Read 2026-10-23.
  8. US Food and Drug Administration. Daily Value on the Nutrition and Supplement Facts Labels. Read 2026-10-23.
  9. European Food Safety Authority. Overview on Tolerable Upper Intake Levels as derived by the SCF and the EFSA NDA Panel. Version August 2025. Read 2026-10-23.
  10. Knapen MH et al. 2013. Three-year low-dose menaquinone-7 supplementation helps decrease bone loss in healthy postmenopausal women. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. PMID 23525894. Read 2026-10-23.
  11. Emaus N et al. 2010. Vitamin K2 supplementation does not influence bone loss in early menopausal women: a randomised double-blind placebo-controlled trial. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. PMID 19937427. Read 2026-10-23.
  12. Zhang Y et al. 2020. Effect of Low-Dose Vitamin K2 Supplementation on Bone Mineral Density in Middle-Aged and Elderly Chinese: A Randomized Controlled Study. Calcified tissue international. PMID 32060566. Read 2026-10-23.
  13. Mott A et al. 2019. Effect of vitamin K on bone mineral density and fractures in adults: an updated systematic review and meta-analysis of randomised controlled trials. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. PMID 31076817. Read 2026-10-23.
  14. Su S et al. 2019. The efficacy and safety of menatetrenone in the management of osteoporosis: a systematic review and meta-analysis of randomized controlled trials. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. PMID 30734066. Read 2026-10-23.
  15. Cockayne S et al. 2006. Vitamin K and the prevention of fractures: systematic review and meta-analysis of randomized controlled trials. Archives of internal medicine. PMID 16801507. Read 2026-10-23.
  16. Geleijnse JM et al. 2004. Dietary intake of menaquinone is associated with a reduced risk of coronary heart disease: the Rotterdam Study. The Journal of nutrition. PMID 15514282. Read 2026-10-23.
  17. Diederichsen ACP et al. 2022. Vitamin K2 and D in Patients With Aortic Valve Calcification: A Randomized Double-Blinded Clinical Trial. Circulation. PMID 35465686. Read 2026-10-23.
  18. Hasific S et al. 2023. Effects of Vitamin K2 and D Supplementation on Coronary Artery Disease in Men: A RCT. JACC. Advances. PMID 38938724. Read 2026-10-23.
  19. Vossen LM et al. 2026. Two Years of Menaquinone-7 Supplementation and Coronary Artery Calcification: A Randomized Clinical Trial. JAMA cardiology. PMID 42268593. Read 2026-10-23.
  20. Vlasschaert C et al. 2020. Vitamin K Supplementation for the Prevention of Cardiovascular Disease: Where Is the Evidence? A Systematic Review of Controlled Trials. Nutrients. PMID 32977548. Read 2026-10-23.
  21. Andrian T et al. 2023. Vitamin K supplementation impact in dialysis patients: a systematic review and meta-analysis of randomized trials. Clinical kidney journal. PMID 38046003. Read 2026-10-23.
  22. Naiyarakseree N et al. 2023. Effect of Menaquinone-7 Supplementation on Arterial Stiffness in Chronic Hemodialysis Patients: A Multicenter Randomized Controlled Trial. Nutrients. PMID 37299386. Read 2026-10-23.
Education, not medical advice. This page is for general information. It does not diagnose or treat any condition and is not a substitute for care from a qualified health professional. Natural does not automatically mean safe. Ask a clinician or pharmacist before changing your care, especially if you take medication, are pregnant or breastfeeding, or have a health condition.